| dc.creator |
Garcia-Guiñón, Antoni |
|
| dc.creator |
Charry, Paola Andrea |
|
| dc.creator |
Jimenez, María |
|
| dc.creator |
Sarra, Josep |
|
| dc.creator |
Delgado, Izarbe |
|
| dc.creator |
Segura de la Torre, Laura |
|
| dc.creator |
Santaliestra, Marta |
|
| dc.creator |
Garcia-Pintos, Marta |
|
| dc.creator |
Gonzalez, Yolanda |
|
| dc.creator |
Senin, Alicia |
|
| dc.creator |
Motlló, Cristina |
|
| dc.creator |
Abella, Eugènia |
|
| dc.creator |
Cabezudo, Elena |
|
| dc.creator |
Granell, Miquel |
|
| dc.creator |
Sancho, Esther |
|
| dc.creator |
Herranz, María José |
|
| dc.creator |
Seres, Yasmina |
|
| dc.creator |
Gironella, Mercedes |
|
| dc.creator |
Soler, Juan Alfons |
|
| dc.creator |
Marti-Tutusaus, Josep Maria |
|
| dc.creator |
Ben Azaiz, Ran |
|
| dc.creator |
Fernandez de Larrea, Carlos |
|
| dc.date |
2025 |
|
| dc.date.accessioned |
2025-11-03T12:15:21Z |
|
| dc.date.available |
2025-11-03T12:15:21Z |
|
| dc.identifier |
https://doi.org/10.1007/s00277-025-06240-1 |
|
| dc.identifier |
1432-0584 |
|
| dc.identifier |
0939-5555 |
|
| dc.identifier |
https://hdl.handle.net/10459.1/468823 |
|
| dc.identifier.uri |
http://fima-docencia.ub.edu:8080/xmlui/handle/123456789/24039 |
|
| dc.description |
Carfilzomib, lenalidomide and dexamethasone (KRd) is still a widely used treatment option for patients with relapsed / refractory multiple myeloma (RRMM). However, there is limited real-world evidence. Here we evaluated the efficacy and safety of KRd in patients with RRMM treated following the standard clinical practice of the hospitals in the Catalan region. This was a retrospective, observational study. The objective response rate (ORR) according to IMWG criteria was the primary endpoint. Secondary endpoints included progression-free survival (PFS) and overall survival (OS). The study planned to include at least 100-150 patients. In total 194 patients were included. Median age was 64 years (range: 40-88) and 56% were male. All patients had received bortezomib. Additionally, 89 patients (46%) had received thalidomide and 29 (15%) lenalidomide. The ORR was 73% (95% CI: 66-79), with 72 patients (37%) having ≥ CR. The ORR was influenced by ISS score, number of previous treatments and exposure to lenalidomide. The median PFS was 26 months and 2-years OS rate 70%. The ISS stage and LDH levels were independent prognostic factors of survival. In conclusion, the KRd scheme led to a good effectiveness comparable safety profile to the phase III clinical trial in patients with RRMM. |
|
| dc.language |
en |
|
| dc.publisher |
Springer |
|
| dc.relation |
Reproducció del document publicat a: https://doi.org/10.1007/s00277-025-06240-1 |
|
| dc.relation |
Annals of Hematology, 2025, vol. 104, núm. 2 |
|
| dc.rights |
cc-by-nc (c) The Authors, 2025 |
|
| dc.rights |
Attribution-NonCommercial 4.0 International |
|
| dc.rights |
info:eu-repo/semantics/openAccess |
|
| dc.rights |
http://creativecommons.org/licenses/by-nc/4.0/ |
|
| dc.subject |
Carfilzomib, lenalidomide and dexamethasone |
|
| dc.subject |
Real-world |
|
| dc.subject |
Relapsed/refractory multiple myeloma |
|
| dc.title |
Real-world evidence of Carfilzomib, Lenalidomide and Dexamethasone (KRD) Scheme in patients with relapsed / refractory multiple myeloma |
|
| dc.type |
info:eu-repo/semantics/article |
|
| dc.type |
info:eu-repo/semantics/publishedVersion |
|